Interv Akut Kardiol. 2005;4(2):70-73

PLASMA NT-proBNP: A SENSITIVE MARKER OF THE CLINICAL STATUS IN PATIENTS WITH ACUTE HEART FAILURE

Radek Pudil5, Miloš Tichý1, Jaroslav Gregor2, Rudolf Praus5, Václav Bláha3, Jan Vojáček5,4, prof. MUDr. Jaroslav Malý CSc5
1 Ústav klinické biochemie a diagnostiky FN a LF UK Hradec Králové
2 II. interní klinika LF UK a Fakultní nemocnice, Hradec Králové
3 Fakulta vojenského zdravotnictví Univerzity obrany, Hradec Králové
4 Kardiocentrum dospělých, oddělení invazivní kardiologie interní kliniky 2. LF UK a FN Motol, Praha
5 I. interní klinika Fakultní nemocnice v Hradci Králové

The aim of the study was to compare clinical symptoms, plasma NT-proBNP levels, cardiothoracic ratio and echocardiographic parameters in patients with acute left ventricular failure. Study population consisted of 96 patients (pts) (67.63 ± 10.77 years, 45 females), 9 of them had symptoms of lung oedema, and 6 of them had cardiogenic shock. The study showed a significant increase in plasma NT-proBNP in all patients (8 575.89 ± 9 665.02 pg/ml, vs control group 91.27 ± 76.63 pg/ml, p < 0.001). Significant differences have been found in plasma NT-proBNP levels depending on the degree of clinical severity (in pts with lung oedema 9 373.67 ± 6 899.29 pg/ml, in pts with cardiogenic shock 28 998.67 ± 6 813.59 pg/ml). While the cardiothoracic ratio was increased in all patients (0.59 ± 0.06, vs. 0.41 ± 0.04, p < 0.001), there were no significant differences between subgroups according to clinical severity. Similar findings were observed in other parameters (left ventricle dimensions, ejection fraction, left ventricle mass) which significantly differed from the control group, but there were no differences between subgroups according to clinical severity. Vena cava inferior diameter was increased in all patients (22.17 ± 3.38 cm, vs. 15.39 ± 1.89 cm, p < 0.001) with a trend to increase in more severe failure. The study showed that plasma NT-proBNP at the time of admission can reflect the degree of heart failure accurately and is sometimes more sensitive than some other commonly used clinical parameters.

Keywords: Key words: acute heart failure, plasma NT-proBNP, ejection fraction, cardiothoracic ratio.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pudil R, Tichý M, Gregor J, Praus R, Bláha V, Vojáček J, Malý J. PLASMA NT-proBNP: A SENSITIVE MARKER OF THE CLINICAL STATUS IN PATIENTS WITH ACUTE HEART FAILURE. Interv Akut Kardiol. 2005;4(2):70-73.
Download citation

References

  1. Denus S, Pharand C, Williamson D. Brain Natriuretic Peptide in the Management of Heart Failure. Chest 2004; 125: 652-668. Go to original source... Go to PubMed...
  2. Tjeerdsma G, de Boer RA, Boomsma F, van den Berg MP, Pinto YM, van Veldhuisen DJ. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol. 2002; 86: 143-149. Go to original source... Go to PubMed...
  3. Cappellin E, Gatti R, Spinella P, De Palo CB, Woloszczuk W, Maragno I, De Palo EF. Plasma atrial natriuretic peptide (ANP) fragments proANP (1-30) and proANP (31-67) measurements in chronic heart failure: a useful index for heart transplantation? Clin Chim Acta. 2001; 310: 49-52. Go to original source... Go to PubMed...
  4. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J. 2003; 24: 1735-1743. Go to original source... Go to PubMed...
  5. Bettencourt P, Frioes F, Azevedo A, Dias P, Pimenta J, Rocha-Goncalves F, Ferreira A. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol. 2004; 93: 45-48. Go to original source... Go to PubMed...
  6. Latini R, Masson S, Anand I, Salio M, Hester A, Judd D, Barlera S, Maggioni AP, Tognoni G, Cohn JN; For the Val-HeFT Investigators. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25: 292-299. Go to original source... Go to PubMed...
  7. Daly C, Fox K, Henein M. Natriuretic peptides in the diagnosis of heart disease-first amongst equals? Int J Cardiol. 2002; 84: 107-113. Go to original source... Go to PubMed...
  8. Hall C. Essential biochemistry and pathophysiology of NT-pro BNP.Eur J Heart Failure 2004; 6: 257-260. Go to original source... Go to PubMed...
  9. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of probrain natriuretic peptide in human plasma. Clin Chim Acta. 2003; 334: 233-239. Go to original source... Go to PubMed...
  10. Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, Sugita K, Yamada K. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta. 2002; 316: 129-135. Go to original source... Go to PubMed...
  11. Hammemer-Lercher A, Neubauer E, Muller S, Pachinger O, Puschendorf B, Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clinica Chimica Acta 2001; 310: 193-197. Go to original source... Go to PubMed...
  12. Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin Chim Acta. 1999; 285: 169-172. Go to original source... Go to PubMed...
  13. Ishii J, Nomura M, Ito M, Naruse H, Mori Y, Wang JH, Ishikawa T, Kurokawa H, Kondo T, Nagamura Y, Ezaki K, Watanabe Y, Hishida H. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta. 2000; 301: 19-30. Go to original source... Go to PubMed...
  14. Cowie MR, Jourdain P, Maisel A, Dahlstrom U, Follath F, Isnard R, Luchner A, McDonagh T, Mair J, Nieminen M, Francis G. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J. 2003; 24: 1710-1718. Go to original source... Go to PubMed...
  15. Morrison K, Harrison A, Krishnawamy P, Kazanegra R, Clopton P, Maisel A. Utilitity of a Rapid B.-Natriuretic Peptide Assay in Differentiating Congestive Heart Failure from Lung Disease in Patients Presenting With Dyspnea. J Am Coll Cardiol 2002; 39: 202-209. Go to original source... Go to PubMed...
  16. Schoiller NB, Shah PM, Crawford M, et al. Reccommendations for quantification of the left ventricle by two dimensional echocardiography: American Society of Echocardiography Committee on Standards Subcommittee. J Am Soc Echocardiography 1989; 2: 358-367. Go to original source... Go to PubMed...
  17. Sahn DJ, DeMaria A, Kisso J, Weyman A. The Committee on M-Mode Standardization of the American Society of Echocardiography: Recommendations regarding quantitation in M-mode echocardiography. Results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083. Go to original source... Go to PubMed...
  18. Devereux RB, Koren MJ, deSimone G, Okin PM, Kligfield P. Methods for detection of left ventricular hypertrophy: Application to hypertensive heart disease. Eur. Heart J. 1993; 14: 8-15. Go to original source... Go to PubMed...
  19. Remme WJ, Swedberg,K. Guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001; 22: 1527-1560. Go to original source... Go to PubMed...
  20. Guidelines for the evaluation and management of heart failure. Report of the ACC/ AHA task force on practice guidelines. J Am Coll Cardiol 1995; 26: 1376-1398.
  21. Sutton T M, Stewart RA, Gerber IL, West TM, Richards M, Yandle TG. Plasma Natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 2003; 41: 2280-2287. Go to original source... Go to PubMed...
  22. Vorvouri E, Schinkel A, Roelandt J, Boosma F, Sianos G, Bountioukos M, Sozzi F, Rizzelo V, Bax J, Karvounis H, Poldermans D. Screening for the left ventricular dysfunction using a hand-carried cardiac ultrasound device. Eur J of Heart Failure 2003; 5: 767-774. Go to original source... Go to PubMed...
  23. Maisel A, McCord J, Nowak R, Hollander J, Wu A, Duc P, Omland T, et al. Bedside B.type Natriuretic peptide in the emergency Diagnosis of heart failure with reduced or preserved ejection fraction. J AM Coll Cardiol 2003; 41: 2010-7i. Go to original source... Go to PubMed...
  24. Clerico A, Edmin M. Diagnostic Accuracy and Prognostic Relevance of the Measurement of cardiac Natriuretic Peptides: A Review. Clin Chem 2004; 6: 33-50. Go to original source... Go to PubMed...
  25. Vítovec J, Špinarová L. Natriuretické peptidy -Diagnostika a léčba. Remedia 2004; 14: 177-181.
  26. Oral I. Natrouretické peptidy - současný stav klinického využití jejich stanovení. Vnitřní Lék 2003; 49: 521-523.




Interventional Cardiology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.